The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Palbociclib plus tamoxifen ± goserelin in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (BC): PATHWAY, an Asian international double-blind randomized phase 3 trial—Final overall survival (OS) analysis.
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; EuroPharma; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - ACT Genomics; AstraZeneca; Daiichi Sankyo; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Eisai; Gilead Sciences; MSD; Novartis
 
Emi Noguchi
No Relationships to Disclose
 
Takashi Yamanaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Gilead Sciences; Kyowa Kirin; Lilly; Novartis; Pfizer
Consulting or Advisory Role - Daiichi Sankyo; Lilly; Pfizer
 
Hirofumi Mukai
Honoraria - Taiho Pharmaceutical; Takeda
 
Rikiya Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Exact Sciences; Kyowa Kirin International; Lilly Japan; MSD Oncology; Nihonkayaku; Novartis
 
Chi-Feng Chung
Consulting or Advisory Role - AstraZeneca; Daichi Sankyo; EirGenix; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/UCB Japan; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); CENTESSA PHARMACEUTICAL (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Kyung-Hun Lee
Honoraria - AstraZeneca Canada; Everest Medicine; Lilly; Novartis; Pfizer
 
Soo Chin Lee
Honoraria - ACT Genomics; AstraZeneca; Daiichi Sankyo; DKSH; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; MSD; Novartis; Pfizer; Roche
Research Funding - ACT Genomics; Eisai; Karyopharm Therapeutics; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; Pfizer; Roche
 
Tsutomu Iwasa
No Relationships to Disclose
 
Yoon Sim Yap
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly/DKSH; MSD; Novartis; Olema Pharmaceuticals; Pfizer; Roche
Research Funding - Merck Sharp & Dohme
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; DKSH; MSD; Novartis; Pfizer
 
Yoshiko Umeyama
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Kazuki Sudo
Honoraria - AstraZeneca; Eisai; Janssen; MSD; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - MSD; Pfizer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Gilead Sciences; Loxo/Lilly; Merck; MSD; Pfizer; PRA Health Sciences; Takeda
 
Tomomi Hata
No Relationships to Disclose
 
Aya Kuchiba
Honoraria - Chugai Pharma
 
Taro Shibata
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - AstraZeneca; Otsuka; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yasuhiro Fujiwara
Other Relationship - Chief Executive of Pharmaceuticals and Medical Devices Agency, regulatory agency of Japan, and contributed to this trial until March 2019
 
Kenji Tamura
Research Funding - Lilly
 
Kan Yonemori
Honoraria - Asterias Biotherapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Genmab; Gilead Sciences; Lilly Japan; Merck KGaA; MSD Oncology; Novartis; Ono Pharmaceutical; PDRadiopharma; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; EP biopharma; GlaxoSmithKline; Haihe Pharmaceutical; Henlius; Lilly Japan; MSD; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)